» Articles » PMID: 36367609

Expression Levels of NONO, a Nuclear Protein Primarily Involved in Paraspeckles Function, Are Associated with Several Deregulated Molecular Pathways and Poor Clinical Outcome in Multiple Myeloma

Overview
Journal Discov Oncol
Publisher Springer
Specialty Oncology
Date 2022 Nov 11
PMID 36367609
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The NONO protein belongs to the multifunctional family of proteins that can bind DNA, RNA and proteins. It is located in the nucleus of most mammalian cells and can affect almost every step of gene regulation. Dysregulation of NONO has been found in many types of cancer; however, data regarding its expression and relevance in Multiple Myeloma (MM) are virtually absent.

Methods: We took advantage of a large cohort of MM patients enrolled in the Multiple Myeloma Research Foundation CoMMpass study to elucidate better the clinical and biological relevance of NONO expression in the context of the MM genomic landscape and transcriptome.

Results: NONO is overexpressed in pathological samples compared to normal controls. In addition, higher NONO expression levels are significant independent prognostic markers of worse clinical outcome in MM. Our results indicate that NONO deregulation may play a pathogenetic role in MM by affecting cell cycle, DNA repair mechanisms, and influencing translation by regulating ribosome biogenesis and assembly. Furthermore, our data suggest NONO involvement in the metabolic reprogramming of glucose metabolism from respiration to aerobic glycolysis, a phenomenon known as the 'Warburg Effect' that supports rapid cancer cell growth, survival, and invasion.

Conclusion: These findings strongly support the need of future investigations for the understanding of the mechanisms of deregulation and the biological role and activity of NONO in MM.

Citing Articles

The pleiotropic nature of NONO, a master regulator of essential biological pathways in cancers.

Ronchetti D, Traini V, Silvestris I, Fabbiano G, Passamonti F, Bolli N Cancer Gene Ther. 2024; 31(7):984-994.

PMID: 38493226 PMC: 11257950. DOI: 10.1038/s41417-024-00763-x.


Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines.

Mereu E, Abbo D, Paradzik T, Cumerlato M, Bandini C, Labrador M Cancers (Basel). 2023; 15(8).

PMID: 37190128 PMC: 10137151. DOI: 10.3390/cancers15082199.

References
1.
Bond C, Fox A . Paraspeckles: nuclear bodies built on long noncoding RNA. J Cell Biol. 2009; 186(5):637-44. PMC: 2742191. DOI: 10.1083/jcb.200906113. View

2.
Munshi N, Anderson K . New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013; 19(13):3337-44. PMC: 4112820. DOI: 10.1158/1078-0432.CCR-12-1881. View

3.
Shav-Tal Y, Zipori D . PSF and p54(nrb)/NonO--multi-functional nuclear proteins. FEBS Lett. 2002; 531(2):109-14. DOI: 10.1016/s0014-5793(02)03447-6. View

4.
Borisov N, Sergeeva A, Suntsova M, Raevskiy M, Gaifullin N, Mendeleeva L . Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles. Front Oncol. 2021; 11:652063. PMC: 8083158. DOI: 10.3389/fonc.2021.652063. View

5.
Koppenol W, Bounds P, Dang C . Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011; 11(5):325-37. DOI: 10.1038/nrc3038. View